Patent · US Expired

Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same

US5981216A · kind A · utility

53Cited by
3References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 7, 1995
Grant dateNov 9, 1999
Priority date
Expiry dateJun 7, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2830/85
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

A myeloma cell-line transformed with a vector including a gene coding for a eukariotic polypeptide and a non-immunolglobulin promoter such that expression occurs of the gene coding for the eukariotic polypeptide, directed by the non-immunoglobulin promoter. The promoter may be a viral promoter, such as an SV40 promoter, a Rous sarcoma virus long terminal repeat or a Moloney murine leukemia long terminal repeat, or a non-viral promoter such as the mouse metallothionein promoter. Rat and mouse host myeloma cell-lines such as the rat YB/2/3.0 Ag20 hybridoma, the mouse SP-20 Ag hybridoma and the mouse NSO hybridoma are employed. The production of tissue plasminogen activator (tPA) is exemplified.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.